pyrazines has been researched along with Phlebitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Takashima, S; Yokota, N | 1 |
| Conrad, CA; Edwards, CL; Forman, A; Freedman, RS; Grothey, A; Grove, W; Hasenburg, A; Kavanagh, JJ; Kudelka, AP; Meyers, CA; Varma, D; Verschraegen, CF | 1 |
| Gaillarde, B; Nove-Josserand, G; Ortonne, JP; Philippe, LP; Plauchu, M; Pugiat, M | 1 |
1 trial(s) available for pyrazines and Phlebitis
| Article | Year |
|---|---|
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Carbamates; Carcinoma; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dyspnea; Female; Humans; Hyponatremia; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Phlebitis; Pyrazines; Pyridines; Survival Rate; Treatment Outcome | 1998 |
2 other study(ies) available for pyrazines and Phlebitis
| Article | Year |
|---|---|
Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythema; Humans; Injections, Subcutaneous; Multiple Myeloma; Phlebitis; Pyrazines | 2012 |
[Value of pyrazinobutazone in the treatment of various inflammatory conditions].
Topics: Anti-Inflammatory Agents; Arthritis; Drug Tolerance; Neuralgia; Osteoarthritis; Osteoporosis; Phenylbutazone; Phlebitis; Pyrazines; Rheumatic Diseases; Spondylitis | 1972 |